Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

BMC Cancer

Elena Barbaria¹  Vanessa Hollerieth¹  Rouven Arnold¹  Birgit Luber¹  Corinna Heck¹  Simone Keller¹  Gwen Zwingenberger¹  Karolin Ebert¹  Elba Raimúndez²  Jan Hasenauer³  Robert Geffers⁴  Julian Mattes⁵ 

[1]Fakultät für Medizin, Technische Universität München, Klinikum rechts der Isar, Institut für Allgemeine Pathologie und Pathologische Anatomie, 81675, München, Germany

[2]Helmholtz Zentrum München-German Research Center for Environmental Health, Institute of Computational Biology, 85764, Neuherberg, Germany

[3]Center for Mathematics, Technische Universität München, 85748, Garching, Germany

[4]Helmholtz Zentrum München-German Research Center for Environmental Health, Institute of Computational Biology, 85764, Neuherberg, Germany

[5]Center for Mathematics, Technische Universität München, 85748, Garching, Germany

[6]Faculty of Mathematics and Natural Sciences, University of Bonn, 53113, Bonn, Germany

[7]Helmholtz Zentrum für Infektionsforschung, 38124, Braunschweig, Germany

[8]MATTES Medical Imaging GmbH, A-4232, Hagenberg, Austria

关键词: Trastuzumab;    Cetuximab;    Afatinib;    Gastric cancer;    Motility;    Phosphoprotein;    Gene expression;   

DOI  :  10.1186/s12885-020-07540-7

来源: Springer

【 摘 要 】

BackgroundGastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer death worldwide. The molecular mechanisms of action for anti-HER-family drugs in gastric cancer cells are incompletely understood. We compared the molecular effects of trastuzumab and the other HER-family targeting drugs cetuximab and afatinib on phosphoprotein and gene expression level to gain insights into the regulated pathways. Moreover, we intended to identify genes involved in phenotypic effects of anti-HER therapies.MethodsA time-resolved analysis of downstream intracellular kinases following EGF, cetuximab, trastuzumab and afatinib treatment was performed by Luminex analysis in the gastric cancer cell lines Hs746T, MKN1, MKN7 and NCI-N87. The changes in gene expression after treatment of the gastric cancer cell lines with EGF, cetuximab, trastuzumab or afatinib for 4 or 24 h were analyzed by RNA sequencing. Significantly enriched pathways and gene ontology terms were identified by functional enrichment analysis. Furthermore, effects of trastuzumab and afatinib on cell motility and apoptosis were analyzed by time-lapse microscopy and western blot for cleaved caspase 3.ResultsThe Luminex analysis of kinase activity revealed no effects of trastuzumab, while alterations of AKT1, MAPK3, MEK1 and p70S6K1 activations were observed under cetuximab and afatinib treatment. On gene expression level, cetuximab mainly affected the signaling pathways, whereas afatinib had an effect on both signaling and cell cycle pathways. In contrast, trastuzumab had little effects on gene expression. Afatinib reduced average speed in MKN1 and MKN7 cells and induced apoptosis in NCI-N87 cells. Following treatment with afatinib, a list of 14 genes that might be involved in the decrease of cell motility and a list of 44 genes that might have a potential role in induction of apoptosis was suggested. The importance of one of these genes (HBEGF) as regulator of motility was confirmed by knockdown experiments.ConclusionsTaken together, we described the different molecular effects of trastuzumab, cetuximab and afatinib on kinase activity and gene expression. The phenotypic changes following afatinib treatment were reflected by altered biological functions indicated by overrepresentation of gene ontology terms. The importance of identified genes for cell motility was validated in case of HBEGF.

【 授权许可】

CC BY